Literature DB >> 8147891

Clearance of circulating endothelin-1 by ETB receptors in rats.

T Fukuroda1, T Fujikawa, S Ozaki, K Ishikawa, M Yano, M Nishikibe.   

Abstract

Exogenous endothelin (ET) is rapidly cleared from the circulation. We investigated which ET receptor subtypes (ETA and ETB) participate in ET-1 clearance. Following an intravenous (i.v.) bolus dose of [125I]ET-1 in anesthetized rats, radioactivity was rapidly cleared from the circulation and trapped by the lungs, kidneys and liver. Tissue distribution of the radioactivity was significantly inhibited in the lungs and kidneys, but not in the liver by infusion of the ETB antagonist BQ-788 (0.1 mg/kg/min i.v.), and the ET-1 clearance rate was reduced, while the ETA antagonist BQ-123 had no such effect. Furthermore, in isolated perfused rat lungs, about 80% of bolus-injected [125I]ET-1 was retained by the lungs after one passage. The retention of ET-1 was significantly inhibited by infusion of 1 microM BQ-788, but not BQ-123. These results suggest that ETB receptors play an important role in the clearance of ET-1.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8147891     DOI: 10.1006/bbrc.1994.1395

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  114 in total

1.  Potential role of endothelin receptor antagonists in the setting of cardiopulmonary bypass: relevance to myocardial performance.

Authors:  A Ergul; C Joffs; A C Walker; F G Spinale
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

2.  Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist.

Authors:  Paul L M van Giersbergen; Jasper Dingemanse
Journal:  Eur J Clin Pharmacol       Date:  2006-04-25       Impact factor: 2.953

Review 3.  Hemodynamic effects of bosentan in patients with chronic heart failure.

Authors:  W Kiowski; G Sütsch; E Oechslin; O Bertel
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

4.  Cooperative role of ETA and ETB receptors in mediating the diuretic response to intramedullary hyperosmotic NaCl infusion.

Authors:  Erika I Boesen; David M Pollock
Journal:  Am J Physiol Renal Physiol       Date:  2010-09-15

5.  Contrasting effects of intervention with ETA and ETB receptor antagonists in hypertension induced by angiotensin II and high-salt diet.

Authors:  Erika I Boesen; Jennifer S Pollock; David M Pollock
Journal:  Can J Physiol Pharmacol       Date:  2010-08       Impact factor: 2.273

6.  Acute effect of a dual ETA-ETB receptor antagonist on pulmonary arterial vasculature in preterm lamb fetuses with surgically induced diaphragmatic hernia.

Authors:  Eleuthère Stathopoulos; Pierre-Henri Rolland; Géraldine Héry; Catherine de Magnée; Olivier Paut; Emmanuelle Couchot; Olivier Leprêtre; Jean-Michel Guys; Pascal de Lagausie
Journal:  Pediatr Surg Int       Date:  2010-08-10       Impact factor: 1.827

7.  Regional quantification of muscarinic acetylcholine receptors and β-adrenoceptors in human airways.

Authors:  T Ikeda; A S M Anisuzzaman; H Yoshiki; M Sasaki; T Koshiji; J Uwada; A Nishimune; H Itoh; I Muramatsu
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

8.  Endothelin-1 response to glucose and insulin among African Americans.

Authors:  Stephanie DeLoach; Yonghong Huan; Constantine Daskalakis; Bonita Falkner
Journal:  J Am Soc Hypertens       Date:  2010-08-21

9.  Impact of endothelin A receptor antagonist selectivity in chronic nitric oxide synthase inhibition-induced fetal growth restriction in the rat.

Authors:  Mark G Neerhof; Sylvia Synowiec; Saira Khan; Larry G Thaete
Journal:  Hypertens Pregnancy       Date:  2010       Impact factor: 2.108

10.  ETB receptor contribution to vascular dysfunction in postmenopausal women.

Authors:  Megan M Wenner; Kelly N Sebzda; Andrew V Kuczmarski; Ryan T Pohlig; David G Edwards
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-04-24       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.